1 / 26

Buprenorphine During Pregnancy: Maternal and Infant Outcomes

Buprenorphine During Pregnancy: Maternal and Infant Outcomes. Alane B. O’Connor DNP, FNP Faculty, Maine Dartmouth Family Medicine Residency Adjunct Instructor, Dartmouth Medical School. Disclosures.

yeriel
Download Presentation

Buprenorphine During Pregnancy: Maternal and Infant Outcomes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Buprenorphine During Pregnancy: Maternal and Infant Outcomes Alane B. O’Connor DNP, FNP Faculty, Maine Dartmouth Family Medicine Residency Adjunct Instructor, Dartmouth Medical School

  2. Disclosures • I do not have any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of this education program. • Use of buprenorphine while breastfeeding is off label.

  3. Outline • Brief introduction to buprenorphine, scope of opioid addiction problem, particularly during pregnancy. • Latest data on use of buprenorphine during pregnancy. • Breastfeeding rates at MDFMR; potential impact of breastfeeding on neonatal abstinence syndrome. • Challenges of monitoring/caring for infants born to mothers taking more than one substance that can cause a withdrawal syndrome.

  4. Buprenorphine • FDA approved (2002) medication for the treatment of opioid dependence. • Partial agonist for mu opioid receptor; high affinity, low activity. • Monotherapy during pregnancy; dissolved sublingually. • MAT recommended for opioid dependence during pregnancy, fetal risk of intoxication/withdrawal. • Methadone is standard of care during pregnancy. • If methadone is refused or unavailable, buprenorphine is an alternative (US SAMHSA). • Infants exposed to opioids during pregnancy are at risk for neonatal abstinence syndrome (NAS). • Finnegan scoring system. • Irritability, tremors, poor feeding/sleeping, GI distress, respiratory complications.

  5. The scope of the problem • 11% of women of childbearing age used illicit drugs in the past month. • 4.5% of all pregnant women. • Pregnant teens at greatest risk (16% ). • May be as high as 25%. • Maine leads the US (8x national average) in per capita rate of residents seeking treatment for addiction to painkillers. • Maine: 165 DABs in 2005, 667 DABs in 2011. • More Mainers die of drug overdose than in automobile accidents.

  6. Our program at MDFMR • First delivery December 2007; more than 70 deliveries since. • Prenatal, intrapartum, postpartum care for mom; care for infants in hospital and after birth. • Integrated care model. • Offer medical care, MAT with buprenorphine and psychological care in one setting. • Research approved by MaineGeneral IRB.

  7. Challenges of studying opioid dependent pregnant women. • Ethical considerations of studying drug dependent pregnant women. • Limited data available about buprenorphine during pregnancy. • Measuring opioid use: • urine toxicology; • self-report. • Polysubstance use. • Paying for negative urine drug screens. • Impact of poverty, poor nutrition, lack of access to prenatal care on outcomes.

  8. Previous data are limited… • Few randomly controlled trials. • 3 randomized controlled studies (2 of 3 had fewer than 10 women). • MOTHER : • 175 opioid dependent pregnant women in 8 sites (58 delivered on buprenorphine). • Double-blind, double-dummy, flexible-dosing, randomized, controlled study comparing buprenorphine to methadone. • Prospective studies (US, Europe). • Only 1 with more than 100 women delivering on buprenorphine. • Case reports and retrospective chart reviews. • O’Connor A, Alto W, Musgrave K, et al. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: Reports on maternal and infant outcomes. Journal of the American Board of Family Medicine. 2011;24(2):194-201.

  9. Methadone vs. Buprenorphine: Maternal Outcomes • MOTHER: • No significant differences in 6 maternal outcomes : • Weight gain. • Number of OB visits. • Incidence of cesarean section. • Abnormal presentation of fetus. • Use of analgesia during delivery. • Positive urine drug screen at delivery. • Maternal methadone exposure associated with: • Increased incidence of non-serious medical events (variations HR, BP).

  10. Methadone vs. Buprenorphine: Fetal Outcomes • MOTHER: • Fetuses (32-35 wks): methadone condition showed more motor activity suppression, shorter duration movements than buprenorphine condition. • Fetuses (31-33 wks): higher incidence of non-reactive non-stress tests for methadone group vs. buprenorphine group. • Long term implications unknown.

  11. Methadone vs. Buprenorphine: Infant Outcomes • MOTHER: • When compared to buprenorphine, infants exposed to methadone had: • More severe NAS: Peak NAS score 12.8 vs. 11.0; • Longer duration NAS treatment: 9.9 days vs. 4.1 days; • Longer overall hospitalization: 17.5 days vs. 10.0 days; • Required more morphine for NAS treatment:10.4 mg vs. 1.1 mg. • No significant difference in number of infants treated for NAS (57% methadone vs. 47% buprenorphine).

  12. Treatment options • Treatment of opioid dependent pregnant women must be individualized. • Comprehensive: medical (OB, pediatric), psychological care, social services, public health nursing, etc. • Risk-benefits of methadone, buprenorphine. • Previous recovery attempts, successes. • Patient preference (informed consent). • Polysubstance use. • Inpatient vs. outpatient buprenorphine initiation. • Pregnancy, substance abuse outcomes improved when care provided in same setting. • Buprenorphine first line therapy?

  13. Breastfeeding and Buprenorphine • Very limited previous literature. • Appears safe. • US DHHS “not contraindicated,” “use professional judgment.” • Likely minimal infant exposure. • Concentration breast milk similar to maternal serum levels but poor bioavailability. • Relative ingestion per kg of infant body weight less than 1% of dose per kg weight mother.

  14. Breastfeeding and Buprenorphine • Lack of professional recommendations leads to inconsistencies across institutions: • Negative urine toxicology at admission? • No evidence of illicit drug use in third trimester? • Maternal intoxication at birth (pump and dump first feed only)? • “Abuse of narcotics” not contraindication to breastfeeding? • Decision should be on case by case basis after weighing benefits and risks if mother is not able to remain abstinent?

  15. ABM recommendations • Breastfeeding okay if: • Engaged in substance abuse treatment; • Received consistent prenatal care; • Abstained from illicit substance use in 90 days prior to delivery. • Breastfeeding NOT okay if: • Not engaged (or planning to engage) in substance abuse treatment; • Relapsed in the 30 days prior to delivery. • ???: • Relapsed in the 30 to 90 days prior to delivery; • Recently entered treatment; • Maintained sobriety only in an inpatient setting.

  16. Breastfeeding and Buprenorphine • Historically, opioid dependent pregnant women have low rates of breastfeeding. • 3 previous studies with breastfeeding rates: • 50% (Fischer et al., 2006); • 45% (Wachman et al., 2010); • 21% (Lejeune et al., 2006). • At MDFMR, 78% breastfed at delivery, 65% still breastfeeding at 2 months. • Significantly more likely to breastfeed at delivery (p<.001) than those previously studied.

  17. Why more likely to breastfeed? • Born at Baby Friendly Hospital? • Only 45% at BMC, also Baby Friendly. • Women in Maine more likely to breastfeed? • 73.5% compared to US rate 74.6%. • Unique integrated medical behavioral health model? • Maybe. Reduces barriers to breastfeeding hypothesized by other authors. • Superb support of nurses/lactation consultants. • Less restrictive policy than other institutions.

  18. Breastfeeding and NAS • 52 maternal-infant pairs: • 41 breastfeeding, 11 non-breastfeeding. • Method by choice, except 1 maternal-infant pair. • No differences in exposure to other substances that may cause withdrawal syndrome: illicit substances, tobacco, antidepressants. • Breastfeeding infants: • Less likely to require NAS treatment (27% vs. 45%, p=.204). • Less severe NAS (9.5 vs. 10.4, p=.390). • Experienced NAS resolution earlier (68.6 hrs vs. 82.0 hrs, p=.359). • No difference in infant length of hospitalization. • But not significant (small number of non-breastfed infants = larger standard error than expected).

  19. Breastfeeding and NAS • No previous literature to compare to: • One poster (Brown et al., 2011): • 49% (36/73) of women on buprenorphine breastfeeding. • 36% of breastfeeding infants required NAS treatment vs. 68% of non-breastfed infants, (p=.007). • No information about polysubstance use. • Breastfeeding can be abruptly discontinued. • Difficult to distinguish potential breastfeeding effects from non-pharmacologic NAS interventions that accompany breastfeeding (e.g., swaddling, enhanced skin-to-skin contact).

  20. Polysubstance use and infant withdrawal • Finnegan scoring system only validated for use in opioid withdrawal. • Many substances can cause a withdrawal syndrome in infants. • High rates of polysubstance use (75%) including illicit opioids, amphetamines, cocaine, marijuana, bath salts. • Challenges properly assessing this use. • Majority of women in treatment for opioid dependence (64%) have one or more psychiatric diagnosis beyond opioid dependence. • Majority of women (81%) use tobacco during pregnancy. • Complications of selecting NAS treatment medication.

  21. Substance abuse, depression and pregnancy • High rate of concurrent substance abuse and mental health diagnoses. • Depressed pregnant women who are not treated at risk for poor outcomes. • Decision is based on risk-benefit assessment. • No randomized, controlled trials assessing efficacy and safety of antidepressant drugs during pregnancy. • 30% of infants exposed to SSRIs in 3rd trimester experience withdrawal syndrome: • Irritability, tremor, constant crying, shivering, GI disturbances, increased tonus, eating/sleeping difficulties, and convulsions.

  22. Buprenorphine and antidepressants • 52 maternal-infant pairs: • 6 exposed to antidepressants third trimester, 46 not exposed. • 3 sertraline, 1 each on bupropion, trazodone, amitriptyline. • No differences in exposure to other substances that may cause withdrawal syndrome: illicit substances, tobacco, maternal dose**. • Infants exposed to antidepressants in utero more likely to be preterm (3/6 vs. 4/46, p=0.026). • Impact of concurrent use?

  23. Buprenorphine and antidepressants • 52 maternal-infant pairs (cont’d): • No difference in NAS severity (p=.737). • No difference in NAS treatment rate (p=.608) • No significant difference in length of hospitalization (p=.218) though longer in those exposed to both (9 days vs. 6.9 days). • Time to NAS resolution significantly longer in infants exposed to both buprenorphine and antidepressants (101 hrs vs. 68 hrs) (p=.034). • Why? Shared metabolic pathway in the liver? Variations in placental transfer of substances? • Longer NAS resolution not related to being preterm.

  24. Buprenorphine and antidepressants

  25. Further work… • Ideally more RCTs. • Larger samples to investigate relationship between breastfeeding and NAS as well as concurrent use of buprenorphine and antidepressants. • Integrated assessment tool that can reliably differentiate between prenatal exposure to opioids vs. variety of other substances that cause withdrawal syndromes. • Standardized, evidenced based treatment protocol for NAS including pharmacologic approaches.

  26. Discussion…

More Related